130 related articles for article (PubMed ID: 27650733)
1. Repression of CMIP transcription by WT1 is relevant to podocyte health.
Moktefi A; Zhang SY; Vachin P; Ory V; Henique C; Audard V; Rucker-Martin C; Gouadon E; Eccles M; Schedl A; Heidet L; Ollero M; Sahali D; Pawlak A
Kidney Int; 2016 Dec; 90(6):1298-1311. PubMed ID: 27650733
[TBL] [Abstract][Full Text] [Related]
2. CMIP interacts with WT1 and targets it on the proteasome degradation pathway.
Zhang SY; Fan Q; Moktefi A; Ory V; Audard V; Pawlak A; Ollero M; Sahali D; Henique C
Clin Transl Med; 2021 Jul; 11(7):e460. PubMed ID: 34323419
[TBL] [Abstract][Full Text] [Related]
3. Integration of Cistromic and Transcriptomic Analyses Identifies Nphs2, Mafb, and Magi2 as Wilms' Tumor 1 Target Genes in Podocyte Differentiation and Maintenance.
Dong L; Pietsch S; Tan Z; Perner B; Sierig R; Kruspe D; Groth M; Witzgall R; Gröne HJ; Platzer M; Englert C
J Am Soc Nephrol; 2015 Sep; 26(9):2118-28. PubMed ID: 25556170
[TBL] [Abstract][Full Text] [Related]
4. A murine model of Denys-Drash syndrome reveals novel transcriptional targets of WT1 in podocytes.
Ratelade J; Arrondel C; Hamard G; Garbay S; Harvey S; Biebuyck N; Schulz H; Hastie N; Pontoglio M; Gubler MC; Antignac C; Heidet L
Hum Mol Genet; 2010 Jan; 19(1):1-15. PubMed ID: 19797313
[TBL] [Abstract][Full Text] [Related]
5. New insights into the function of the Wilms tumor suppressor gene WT1 in podocytes.
Morrison AA; Viney RL; Saleem MA; Ladomery MR
Am J Physiol Renal Physiol; 2008 Jul; 295(1):F12-7. PubMed ID: 18385267
[TBL] [Abstract][Full Text] [Related]
6. Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis.
Patek CE; Fleming S; Miles CG; Bellamy CO; Ladomery M; Spraggon L; Mullins J; Hastie ND; Hooper ML
Hum Mol Genet; 2003 Sep; 12(18):2379-94. PubMed ID: 12915483
[TBL] [Abstract][Full Text] [Related]
7. Alternatively spliced isoforms of WT1 control podocyte-specific gene expression.
Lefebvre J; Clarkson M; Massa F; Bradford ST; Charlet A; Buske F; Lacas-Gervais S; Schulz H; Gimpel C; Hata Y; Schaefer F; Schedl A
Kidney Int; 2015 Aug; 88(2):321-31. PubMed ID: 25993318
[TBL] [Abstract][Full Text] [Related]
8. c‑Maf inducing protein inhibits cofilin‑1 activity and alters podocyte cytoskeleton organization.
Yu L; Ye J; Liu Q; Feng J; Gu X; Sun Q; Lu G
Mol Med Rep; 2017 Oct; 16(4):4955-4963. PubMed ID: 28791377
[TBL] [Abstract][Full Text] [Related]
9. Clinical Aspects of WT1 and the Kidney.
Miller-Hodges E
Methods Mol Biol; 2016; 1467():15-21. PubMed ID: 27417956
[TBL] [Abstract][Full Text] [Related]
10. A proteomic investigation of glomerular podocytes from a Denys-Drash syndrome patient with a mutation in the Wilms tumour suppressor gene WT1.
Viney RL; Morrison AA; van den Heuvel LP; Ni L; Mathieson PW; Saleem MA; Ladomery MR
Proteomics; 2007 Mar; 7(5):804-15. PubMed ID: 17295355
[TBL] [Abstract][Full Text] [Related]
11. Functional characterization of WT1 binding sites within the human vitamin D receptor gene promoter.
Lee TH; Pelletier J
Physiol Genomics; 2001 Dec; 7(2):187-200. PubMed ID: 11773605
[TBL] [Abstract][Full Text] [Related]
12. PINCH1 is transcriptional regulator in podocytes that interacts with WT1 and represses podocalyxin expression.
Wang D; Li Y; Wu C; Liu Y
PLoS One; 2011 Feb; 6(2):e17048. PubMed ID: 21390327
[TBL] [Abstract][Full Text] [Related]
13. WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.
Yang Y; Jeanpierre C; Dressler GR; Lacoste M; Niaudet P; Gubler MC
Am J Pathol; 1999 Jan; 154(1):181-92. PubMed ID: 9916932
[TBL] [Abstract][Full Text] [Related]
14. WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin.
Palmer RE; Kotsianti A; Cadman B; Boyd T; Gerald W; Haber DA
Curr Biol; 2001 Nov; 11(22):1805-9. PubMed ID: 11719225
[TBL] [Abstract][Full Text] [Related]
15. Activation of podocyte Notch mediates early Wt1 glomerulopathy.
Asfahani RI; Tahoun MM; Miller-Hodges EV; Bellerby J; Virasami AK; Sampson RD; Moulding D; Sebire NJ; Hohenstein P; Scambler PJ; Waters AM
Kidney Int; 2018 Apr; 93(4):903-920. PubMed ID: 29398135
[TBL] [Abstract][Full Text] [Related]
16. TGF-β1 alters DNA methylation levels in promoter and enhancer regions of the WT1 gene in human podocytes.
Hamatani H; Sakairi T; Ikeuchi H; Kaneko Y; Maeshima A; Nojima Y; Hiromura K
Nephrology (Carlton); 2019 May; 24(5):575-584. PubMed ID: 29851165
[TBL] [Abstract][Full Text] [Related]
17. Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome.
Schumacher VA; Jeruschke S; Eitner F; Becker JU; Pitschke G; Ince Y; Miner JH; Leuschner I; Engers R; Everding AS; Bulla M; Royer-Pokora B
J Am Soc Nephrol; 2007 Mar; 18(3):719-29. PubMed ID: 17267748
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-466o-3p mediates β-catenin-induced podocyte injury by targeting Wilms tumor 1.
Chen Q; Chen J; Wang C; Chen X; Liu J; Zhou L; Liu Y
FASEB J; 2020 Nov; 34(11):14424-14439. PubMed ID: 32888352
[TBL] [Abstract][Full Text] [Related]
19. A mutant form of the Wilms' tumor suppressor gene WT1 observed in Denys-Drash syndrome interferes with glomerular capillary development.
Natoli TA; Liu J; Eremina V; Hodgens K; Li C; Hamano Y; Mundel P; Kalluri R; Miner JH; Quaggin SE; Kreidberg JA
J Am Soc Nephrol; 2002 Aug; 13(8):2058-67. PubMed ID: 12138137
[TBL] [Abstract][Full Text] [Related]
20. Wt1a, Foxc1a, and the Notch mediator Rbpj physically interact and regulate the formation of podocytes in zebrafish.
O'Brien LL; Grimaldi M; Kostun Z; Wingert RA; Selleck R; Davidson AJ
Dev Biol; 2011 Oct; 358(2):318-30. PubMed ID: 21871448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]